Article citationsMore>>

Peng, Z., Liu, T., Wei, J., Wang, A., He, Y., Yang, L., Zhang, X., et al. (2021) Efficacy and Safety of a Novel Anti-HER2 Therapeutic Antibody RC48 in Patients with HER2-Overexpressing, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer: A Single-Arm Phase II Study. Cancer Communications, 41, 1173-1182.
https://doi.org/10.1002/cac2.12214

has been cited by the following article:

• TITLE: Antibody-Coupled Drugs in HER2-Positive Gastric Cancer

  AUTHORS: Baofeng Liu, Yuanmei Dai, Xiaohui Shen, Xiangyang Tian

  KEYWORDS: Antibody-Coupled Drugs, HER2-Positive Gastric Cancer, Review

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.7, July 7, 2023

  ABSTRACT: Antibody drug conjugates (ADCs) are a new class of drugs that combine chemosynthetic drugs with antibody drugs through a linker. Antibody drug conjugates combine the targeting characteristics of traditional antibody drugs with the cytotoxic characteristics of small molecule drugs, while reducing the side effects of both drugs, making them a kind of “biological missile” and representing a relatively new and evolving class of anti-cancer drugs. Antibody-coupled drugs are currently used in many solid tumors, and this article reviews the clinical application of antibody-coupled drugs in HER2-positive gastric cancer.